RNA
Avidity Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.19
−2.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.0M | 18.6M | 10.9M | 9.6M | 9.2M |
| Cost of Revenue | 494.0K | — | — | 2.1M | 1.4M |
| Gross Profit | 35.5M | 18.6M | 10.9M | 7.5M | 7.8M |
| Operating Expenses | |||||
| R&D Expense | 205.4M | 53.8M | 303.6M | 191.0M | 150.4M |
| SG&A Expense | 106.8M | 41.7M | 86.2M | 54.2M | 37.7M |
| General & Admin Expense | 76.7M | 41.7M | 86.2M | 54.2M | 37.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (2.1M) | (1.4M) |
| Total Operating Expenses | 312.2M | 95.4M | 389.8M | 243.1M | 186.8M |
| Cost and Expenses | 312.7M | 95.4M | 389.8M | 245.2M | 188.1M |
| Operating Income (EBIT) | (276.7M) | (76.8M) | (378.9M) | (235.6M) | (178.9M) |
| Non-Operating | |||||
| Interest Income | 16.8M | — | 56.9M | 24.0M | 5.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 16.8M | — | 56.9M | 24.0M | 5.0M |
| Other Non-Op Income/Expense | 17.4M | (12.0K) | 56.6M | 23.4M | 4.9M |
| Non-Operating Income (excl Interest) | (15.0M) | 12.0K | — | — | — |
| EBT (Pre-Tax Income) | (259.3M) | (76.8M) | (322.3M) | (212.2M) | (174.0M) |
| Income Tax Expense | 34.0K | (142.0K) | — | — | — |
| Bottom Line | |||||
| Net Income | (259.3M) | (76.7M) | (322.3M) | (212.2M) | (174.0M) |
| Earnings from Cont. Ops | (259.3M) | (76.7M) | (322.3M) | (212.2M) | (174.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (259.3M) | (76.7M) | (322.3M) | (212.2M) | (174.0M) |
| Per Share | |||||
| Basic EPS | ($5.12) | ($4.48) | ($2.89) | ($2.91) | ($3.34) |
| Diluted EPS | ($5.12) | ($4.48) | ($2.89) | ($2.91) | ($3.34) |
| Revenue Per Share | $2.10 | $1.09 | $0.10 | $0.13 | $0.18 |
| Shares | |||||
| Basic Shares Outstanding | 17.1M | 17.1M | 111.6M | 73.0M | 52.2M |
| Diluted Shares Outstanding | 17.1M | 17.1M | 111.6M | 73.0M | 52.2M |
| Profitability Metrics | |||||
| EBITDA | (260.1M) | (76.5M) | (376.2M) | (233.5M) | (177.5M) |
| D&A | 1.7M | 323.0K | 2.8M | 2.1M | 1.4M |
| EBIT | (261.7M) | (76.8M) | (378.9M) | (235.6M) | (178.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026